NeuroMetrix Shares Rally On FDA Breakthrough Tag For Neurostimulation Device

The FDA has granted Breakthrough Designation to NeuroMetrix Inc's NURO Quell technology for reducing moderate to severe symptoms of chemotherapy-induced peripheral neuropathy (CIPN) that have persisted for at least 6-months following the end of chemotherapy.

  • There are no FDA-approved treatments for CIPN, and those that are used have limited effectiveness and have side effects.
  • Quell is a non-invasive neuromodulation technology covered by 19 U.S. utility patents. 
  • Related content: Benzinga's Full FDA Calendar.
  • It is the only wearable neuromodulator enabled by a proprietary microchip that provides precise, high-power nerve stimulation in a form factor the size of a credit card. 
  • The Quell device utilizes position and motion sensing to adjust stimulation automatically.
  • A National Cancer Institute-funded sham-controlled trial of Quell in CIPN is currently ongoing. 150 patients will be enrolled for six weeks. 
  • The primary outcome measure is the baseline to 6-week change in the EORTC-CIPN20. 
  • Other outcomes include individual CIPN symptoms and objective central descending pain inhibition measures, lower limb sensation threshold, and balance. 
  • The study is expected to complete by the end of 2022.
  • Depending on the trial's outcome, we hope to be positioned for an FDA filing in 2023. 
  • Price Action: NURO shares are up 36.6% at $6.72 during the market session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Long IdeasNewsHealth CareFDAMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!